Citadel Advisors
FHTX icon

Citadel Advisors’s Foghorn Therapeutics FHTX Stock Holding History

Citadel Advisors’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$775K Sell
158,822
-41,191
-21% -$183K ﹤0.01% 8830
2026
Q1 		$956K Buy
200,013
+17,737
+10% +$97.4K ﹤0.01% 7755
2025
Q4 		$984K Buy
182,276
+170,249
+1,416% +$772K ﹤0.01% 7427
2025
Q3 		$58.8K Buy
+12,027
New +$63.8K ﹤0.01% 12111
2024
Q4 		– Sell
-81,204
Closed -$756K – 14764
2024
Q3 		$756K Buy
81,204
+16,354
+25% +$118K ﹤0.01% 7398
2024
Q2 		$373K Buy
64,850
+40,877
+171% +$243K ﹤0.01% 8664
2024
Q1 		$161K Buy
+23,973
New +$133K ﹤0.01% 10660
2023
Q2 		– Sell
-153,072
Closed -$949K – 14600
2023
Q1 		$949K Buy
153,072
+89,291
+140% +$584K ﹤0.01% 6887
2022
Q4 		$407K Sell
63,781
-3,911
-6% -$29.5K ﹤0.01% 8670
2022
Q3 		$581K Buy
+67,692
New +$871K ﹤0.01% 8136
2022
Q2 		– Sell
-58,546
Closed -$892K – 13221
2022
Q1 		$892K Buy
+58,546
New +$803K ﹤0.01% 7972

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Citadel Advisors's FHTX Position: Q2 2026 in Review

Citadel Advisors reduced its Foghorn Therapeutics (FHTX) stake by 21% in Q2 2026, selling an estimated $183K and leaving 158,822 shares worth $775K. The position accounts for ﹤0.01% of the portfolio, ranked #8830.

Citadel Advisors first reported a position in FHTX in Q1 2022 and has held it in 11 quarters since. The position peaked at $984K in Q4 2025. 103 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

  • Citadel Advisors held 158,822 shares of Foghorn Therapeutics worth $775K as of Q2 2026.
  • Citadel Advisors sold 41,191 Foghorn Therapeutics shares in Q2 2026, an estimated $183K.
  • Foghorn Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #8830 holding.
  • Citadel Advisors first reported a position in Foghorn Therapeutics in Q1 2022 and has held it in 11 quarters since.
  • Citadel Advisors's Foghorn Therapeutics position peaked at $984K in Q4 2025.
  • 103 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.